Ligand-based targeted delivery of a peptide modified nanocarrier to endothelial cells in adipose tissue
- 15 October 2010
- journal article
- Published by Elsevier BV in Journal of Controlled Release
- Vol. 147 (2), 261-268
- https://doi.org/10.1016/j.jconrel.2010.07.100
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
This publication has 34 references indexed in Scilit:
- Nanoparticles Targeted With NGR Motif Deliver c-myc siRNA and Doxorubicin for Anticancer TherapyMolecular Therapy, 2010
- Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: In vitro and in vivo studiesEuropean Journal of Pharmaceutics and Biopharmaceutics, 2010
- Affinity manipulation of surface-conjugated RGD peptide to modulate binding of liposomes to activated plateletsBiomaterials, 2008
- Targeted pharmaceutical nanocarriers for cancer therapy and imagingThe AAPS Journal, 2007
- Octaarginine-modified multifunctional envelope-type nanoparticles for gene deliveryGene Therapy, 2007
- Monoclonal Antibody-Based Targeted Therapy in Breast CancerDrugs, 2006
- Differential regulation of Rb family proteins and prohibitin during camptothecin-induced apoptosisOncogene, 2002
- The EGFR as a target for anticancer therapy—focus on cetuximabEuropean Journal Of Cancer, 2001
- Prohibitins act as a membrane-bound chaperone for the stabilization of mitochondrial proteinsThe EMBO Journal, 2000
- Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomesFEBS Letters, 1990